ライフサイエンスコーパス: salvage treatment

1 ts who experienced relapse responded well to salvage treatment.

2 dder cancer (MIBC), reserving cystectomy for salvage treatment.

3 specific antigen levels >/= 0.2 ng/mL or any salvage treatment.

4 mechanism, it may offer a fine strategy for salvage treatment.

5 pendymomas located in eloquent areas or as a salvage treatment.

6 loped early disease progression and required salvage treatment.

7 o have isolated local recurrence amenable to salvage treatment.

8 lant (SCT) was compared with chemotherapy as salvage treatment.

9 Patients that relapse require salvage treatment.

10 cutive follow-up visits or the initiation of salvage treatment.

11 of OPSCC, there is a high rate of successful salvage treatment.

12 nts who relapsed after WBRT were alive after salvage treatment.

13 h BRAF or MEK inhibitors have revolutionised salvage treatment.

14 (bispecific antibody or subsequent CAR T) as salvage treatment.

15 tify resistance patterns to select effective salvage treatments.

16 ions unanswered about optimal first-line and salvage treatments.

17 Both triazoles are strongly recommended salvage treatments.

18 icant advances in supportive care and better salvage treatments.

19 e cancer, including 89 (22%) who received no salvage treatment, 18 (11%) who received salvage radioth

20 After failure, 154 patients (64%) received salvage treatment: 38.3% received lenalidomide, 7.1% bis

21 success rate with stem-cell transplantation salvage treatment administered among patients in both tr

22 iochemical recurrence (BCR) and eligible for salvage treatment after radical prostatectomy with two c

23 nancies has heralded their potential as both salvage treatment and early treatment lines, reducing th

24 l tolerated and show substantial efficacy as salvage treatment and equal or even superior efficacy co

25 0 NHL patients treated with low-dose TBI and salvage treatment and followed-up for 15 years.

26 ould result in additional neurotoxicity from salvage treatments and brain damage by relapsing tumor.

27 The role of salvage treatments and high-dose chemotherapy at relapse

28 We analyzed the salvage treatments and outcomes of 79 patients with mult

29 Ultimately, 7 patients received successful salvage treatment, and 3 died with disease.

30 splatin resistance, which requires intensive salvage treatment, and have a 50% risk of cancer-related

31 6 months after chemoradiotherapy can undergo salvage treatment, and their survival is excellent.

32 Purpose No effective salvage treatments are available for patients with advan

33 juvant treatment for all high-risk cases vs. salvage treatment at the time of prostate-specific antig

34 ion of patients with BCR is pivotal to guide salvage treatment decisions, reduce overtreatment, and l

35 Mastectomies as first salvage treatment for ipsilateral breast tumour recurren

36 SBRT is an effective primary or salvage treatment for mechanically stable spinal metasta

37 d the safety and efficacy of gene therapy as salvage treatment for older XSCID children with inadequa

38 erapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemot

39 The existence of salvage treatment for patients with DLI after TCD alloge

40 matologic effects of single-agent CEP-701 as salvage treatment for patients with refractory, relapsed

41 medicine methods for detecting and planning salvage treatment for prostate cancer local recurrence a

42 Given salvage treatment for recurrent nasopharyngeal carcinoma

43 3/Foxp3 interaction may serve as a potential salvage treatment for recurrent NPC.

44 c survival relative to those who received no salvage treatment (hazard ratio [HR], 0.32 [95% confiden

45 HDCT was the first salvage treatment in 29 patients and second or later sal

46 %, as second-line treatment in 38.4%, and as salvage treatment in 36.2%.

47 treatment in 29 patients and second or later salvage treatment in 72 patients.

48 s indicated by the possibility of successful salvage treatment in more than 70% of PET2-positive pati

49 Assessment of dose-intense M-VAC as salvage treatment in patients who failed to respond to t

50 of patients achieved sustained remissions to salvage treatments, including blinatumomab, inotuzumab,

51 ogenetic abnormalities, sex, and response to salvage treatment is considered, t(8;21) and inv(16) AML

52 Accepted salvage treatment is conventional-dose chemotherapy (CDC

53 A total of 237 post-CAR T salvage treatment lines were used, and patients received

54 embolization as first-line, second-line, and salvage treatment, mOS was 12.0 mo (95% CI, 7.6-23.4 mo)

55 Clinically, with such high cure rates after salvage treatments, most of the controversy focuses now

56 ical and/or local recurrence and received no salvage treatment (n = 397), salvage radiotherapy alone

57 de followed by stem cell reinfusion, for the salvage treatment of GCTs.

58 this study were to quantify the prospects of salvage treatment of patients who did not undergo transp

59 Successful salvage treatment of patients who do not undergo transpl

60 HDCT plays an integral role in the salvage treatment of patients with advanced GCTs.

61 pse (LR) and distant metastases (DM) and the salvage treatment of patients with LR only.

62 ause inhibition of IGF1R offered efficacious salvage treatment of PI3K-delta inhibitor-resistant tumo

63 Thirty patients (79%) received salvage treatment of post-CAR T disease progression, and

64 osurgery has a promising role in primary and salvage treatment of select prostate cancer patients.

65 ld now be considered a standard approach for salvage treatment of severe aplastic anaemia.

66 Radioembolization is a safe and effective salvage treatment option in advanced NET patients with l

67 al fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stab

68 recurrence, or assessment for suitability of salvage treatment or as response assessment within 1-6 m

69 tumor burden that requires intensive ocular-salvage treatment or enucleation.

70 high-dose therapy compared with conventional salvage treatment (OS: 54% v 47%, P = .25; EFS: 53% v 27

71 After salvage treatment, patients with HT had less frequent co

72 irst remission (<12 months vs >/=12 months), salvage treatment phase (first vs second), and age (<55

73 dical prostatectomy or radiation therapy and salvage treatment planning.

74 g trimodality therapy, for whom surveillance/salvage treatment plays a lesser role,(1) in the BMT pop

75 surgical margin status (R0 v R1), PSA before salvage treatment (PSA >= 0.5 v < 0.5 ng/mL), and pathol

76 ts, was designed to study the durability of "salvage" treatment regimens.

77 Thus, salvage treatment remains a controversial topic.

78 Proton beam therapy as a salvage treatment resulted in high local tumor control r

79 ithin the scope of the increasing use of eye-salvage treatment strategies.

80 P, PSMA PET/CT imaging is warranted to guide salvage treatment strategies.

81 anagement approach-advanced relapse is rare, salvage treatment successful, and outcomes excellent, re

82 l to identify recurrence earlier and perform salvage treatments, thereby possibly improving survival

83 or PET2-positive patients (regardless of the salvage treatment they received) and 81% for PET2-negati

84 wever, the ability to effectively administer salvage treatment to patients with radiorecurrent diseas

85 is has been based on historically controlled salvage treatment trials in patients failing or intolera

86 herapy following incomplete resection, or as salvage treatment upon tumor recurrence.

87 NA-treated patients as a result of effective salvage treatment used for transformed disease.

88 Older patients with relapsed ATRT can have salvage treatment using ICE chemotherapy.

89 apsed after fludarabine therapy responded to salvage treatment, usually with fludarabine-based regime

90 emia who were due to receive first or second salvage treatment were randomly assigned (1:1) via an in

91 agnosis, what are the optimal first-line and salvage treatments, what is the role of maintenance ther

92 Salvage treatment with chemotherapy before DLI can help

93 In patients with a long REM1 (>/=3 years), salvage treatment with either repeat FCR or lenalidomide

94 ase recurrence are candidates for aggressive salvage treatment with high-dose chemotherapy and autolo

95 r patients with AL amyloidosis responding to salvage treatment with pomalidomide.

96 In clinical trials, HCV salvage treatment with Sofosbuvir/Velpatasvir/Voxilaprev

97 In clinical trials, hepatitis C virus (HCV) salvage treatment with sofosbuvir/velpatasvir/voxilaprev

98 majority of patients eventually relapse, and salvage treatments with non-cross-resistant compounds ar

99 matologic malignancies subsequently received salvage treatment, with either alkylating agents alone (

100 a on long-term outcomes are available, early salvage treatment would seem the preferable treatment po